Pancragen vs Suprefort
Comparison of Pancragen (Low evidence) and Suprefort (Very Low evidence).
Last updated: February 12, 2026
Pancragen
Suprefort
Overview
Pancragen and Suprefort are both studied in the peptide research space.
Pancragen: A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed by Russian scientist Vladimir Khavinson for pancreatic support.
Suprefort: A cytamin-class peptide supplement derived from pancreatic tissue, part of the Russian bioregulator framework.
Evidence Comparison
| Aspect | Pancragen | Suprefort |
|---|---|---|
| Evidence Level | Low | Very Low |
| Human Studies | 1 | 0 |
| Preclinical Studies | 6 | 5 |
| Total Sources | 8 | 6 |
Key Differences
| Aspect | Pancragen | Suprefort |
|---|---|---|
| Category | Other | Other |
| Evidence Strength | Low | Very Low |
| Total Sources | 8 | 6 |
| Human Studies | 1 | 0 |
Summary
- Pancragen: Low evidence with 8 total sources (1 human)
- Suprefort: Very Low evidence with 6 total sources (0 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.